> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Relieveus Selling Unapproved CBD Products: FDA
- URL: https://www.fdaweb.com/relieveus-selling-unapproved-cbd-products-fda/
- Published: 2019-04-09T12:00:00.000Z
- Updated: 2026-09-15T01:19:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, Drugs, #legacy-id-D5143817

FDA and the Federal Trade Commission (FTC) say Advanced Spine and Pain, Mount Laurel, NJ, which is doing business as Relieveus, is using the Internet to market its CBD Salve, CBD Oil, and CBD for Dogs, which FDA considers to be new, unapproved and misbranded human or animal drugs that may not be marketed as dietary supplements. A joint 3/28 [Warning Letter](https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm634781.htm?ref=fdaweb.com) cites FDA’s legal justification for its position and the many Web site claims that it says establish the products as drugs.

The FTC portion of the letter says it is unlawful to advertise that a product can prevent, treat, or cure human disease unless the manufacturer possesses “competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.”

FTC said it was concerned that one or more of the Web site efficacy claims may not be substantiated by competent and reliable scientific evidence and urged the company to review all its product claims and ensure that they are supported by competent and reliable scientific evidence.

FDA told the company to respond with a list of specific steps taken to correct the violations and prevent their recurrence, with documentation of each step, and a timetable for completion.